Financial Assistance Options

No matter what type of health insurance you have, and even if you have none at all, there may be options available to help you afford your medicine.

Quick Links

Use our financial assistance tool to see which programs may be right for you.


If you have insurance coverage and need help affording Pulmozyme, these programs may help:

Pulmozyme Co-pay Assistance Program

Pulmozyme® (dornase alfa) Co-pay card

With the Pulmozyme Co-pay Assistance Program, eligible patients with commercial insurance could pay as little as $30 for a 30-day supply of Pulmozyme. It covers any additional out-of-pocket costs for Pulmozyme, after you pay $30 for each 30-day supply, up to $10,000 per year.

You may be eligible if you:

  • Have a valid prescription for Pulmozyme for an FDA-approved use
  • Reside in the United States or U.S. Territories
  • Are over the age of 18, or have a Legally Authorized Person over the age of 18 to manage the program
  • Have commercial (private or non-governmental) insurance. This includes plans available through state and federal health insurance exchanges
  • Are not currently receiving Pulmozyme from the Genentech Patient Foundation
  • Are not currently receiving assistance from any other charitable organization for any of your out-of-pocket costs that are covered by the Pulmozyme Co-pay Assistance Program
  • Are not using a state or federal healthcare plan to pay for their medication. This includes, but is not limited to, Medicare, Medicaid and TRICARE

Under the program, the patient will pay a co-pay. After reaching the maximum program benefit, the patient will be responsible for all out-of-pocket expenses. All participants are responsible for reporting the receipt of all program benefits as required by any insurer or by law. No party may seek reimbursement for all or any part of the benefit received through this Program. The program is only valid in the United States and U.S. Territories. This program is void where prohibited by law and shall follow state restrictions in relation to AB-rated generic equivalents (e.g., MA, CA) where applicable. The patient, guardian, prescriber, hospital and any other person using the program agree not to seek reimbursement for all or any part of the benefit received by the patient through the offer of this program. Genentech reserves the right to rescind, revoke or amend the program without notice at any time. Additional terms and conditions apply.

View full TERMS AND CONDITIONS.

Independent Co-pay Assistance Foundations

Independent Co-pay Assistance

An independent co-pay assistance foundation is a charitable organization providing financial assistance to patients with specific disease states, regardless of treatment. Patients who are commercially or publicly insured, including those covered by Medicare and Medicaid, can contact the foundations directly to request assistance. Eligibility requirements, all aspects of the application process, turnaround times and the type or amount of assistance available (if any) can vary by foundation. 

These foundations may be able to help. Please check their websites for up-to-date information.

Independent co-pay assistance foundations have their own rules for eligibility. We have no involvement or influence in independent foundation decision-making or eligibility criteria and do not know if a foundation will be able to help you. We can only refer you to a foundation that supports your disease state. This information is provided as a resource for you. We do not endorse or show preference for any particular foundation. The foundations in this list may not be the only ones that might be able to help you.


If you have financial difficulty or do not have insurance coverage and need help affording Pulmozyme, this program may help:

Genentech Patient Foundation

Genentech Patient Foundation

The Genentech Patient Foundation gives free Pulmozyme to people who have been prescribed this medicine and don’t have insurance or that have financial concerns and meet certain eligibility criteria.

You may be eligible if your insurance coverage and income match one of these situations:

  • Uninsured patients with incomes under $150,000
  • Insured patients without coverage for Pulmozyme with incomes under $150,000
  • Insured patients with coverage for a Genentech medicine:
    • With unaffordable out-of-pocket costs
    • Who have pursued other forms of financial assistance
    • With household size and income within certain guidelines
 

Genentech reserves the right to modify or discontinue the program at any time and to verify the accuracy of information submitted.

Enrollment Process for the Genentech Patient Foundation

If you meet the criteria, and would like to enroll:

  1. Complete the Patient Consent Form, which is available in English and Spanish, below: 
  2. Once you have completed the Patient Consent Form, you can inform your doctor's office and let them know that you are applying for assistance from the Genentech Patient Foundation for the medicine your doctor has already prescribed. Your doctor will have to complete another form called the Prescriber Foundation Form. Both forms are required. No action can be taken until a completed Patient Consent Form and Prescriber Foundation Form have been received.

What to expect next:

  • The request will be processed within 5 business days upon receipt of both required forms
  • You and your provider will be contacted to discuss the application outcome and any next steps

If you have any questions about the criteria please contact a Foundation Specialist at 888-941-3331 (Mon.–Fri., 6AM–5PM PST), or get started by enrolling below.


Not sure which programs may be able to help you? We'll walk you through some potential options with the financial assistance tool.

Tips and links for cystic fibrosis (CF) patients

Tips & Helpful Links

Find information about nutrition, exercise and resources for people living with cystic fibrosis.

  • Commercial insurance: An insurance plan you get from a private health insurance company. This can be insurance from your job, from a plan you bought yourself or from a Health Insurance Marketplace (for example, from HealthCare.gov). Medicare and Medicaid are not considered commercial insurance. 

  • Public insurance: A health insurance plan you get from the federal or state government. This includes Medicare, Medicaid, TRICARE and DoD/VA insurance.

  • For example, a household size of 1 with income of less than $75,000 may meet the criteria for assistance. Add $25,000 for each additional person in the household. There is no maximum number of people you may add.

Indication & Usage

Pulmozyme (dornase alfa) is indicated for daily administration along with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function.

In CF patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring injectable antibiotics.

Important Safety Information

Pulmozyme should not be used in patients who are allergic to any of its ingredients.

Patients may experience the following when using Pulmozyme: change in or loss of their voice, discomfort in the throat, rash, chest pain, red watery eyes, runny nose, lowering of lung function, fever, indigestion, and shortness of breath. There have been no reports of severe allergic reactions caused by the administration of Pulmozyme. Mild to moderate hives and mild skin rash have been observed and have been short-lived.

Pediatric Use

The safety and effectiveness of Pulmozyme have been established in patients 5 years of age and older. While clinical trial data are limited in patients younger than 5 years of age, the use of Pulmozyme should be considered for pediatric CF patients who may experience potential benefit in lung function or who may be at risk of respiratory tract infection.

The safety of Pulmozyme given by daily inhalation for 2 weeks has been studied using 98 CF patients with 65 of them aged 3 months to <5 years (younger group) and 33 aged 5 years to <10 years (older group). The PARI BABY™ reusable nebulizer (which uses a face mask instead of a mouthpiece) was used in patients who were unable to show that they could breathe in or out using their mouth throughout the entire treatment period. Overall, the kind of side effects observed in children was similar to those seen in larger trials in older patients.

You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see full Pulmozyme Prescribing Information for additional Important Safety Information. If you have questions, please discuss them with your CF Care Team.